North America Stem Cell Therapy Market Receives a Rapid Boost in Economy Due to High Emerging Demands by Forecast to 2028
The North America stem cell therapy
market was valued at US$ 1,299.39 million in 2022 and is projected to reach US$
3,582.26 million by 2028; it is expected to grow at a CAGR of 18.4% from 2022
to 2028.
Increasing Research Activities Related
to Stem Cell Therapy for Effective Disease Management is Driving the North
America Stem Cell Therapy Market
Stem cell therapy has been widely investigated across the world.
Stem cells are mainly used to replace dying cells and reconstruct damaged
tissues. Based on the results of extensive stem cell research conducted so far,
many scientists have claimed that these cells could probably be utilized to
generate cures and treatments for diseases such as cancer and cardiovascular
disease. Newly developed stem cell therapies involve replacing disease-causing
cells with stem cells. Many potential treatments involving stem cells are in
different phases of clinical trials. The FDA has also approved a few stem cell
therapies involved in treating complications related to stem cell transplants.
In September 2021, the US Food and Drug Administration (FDA) announced approval
for "Ruxolitinib" for treating "graft-versus-host-disease"
(GVHD) in patients aged 12 and above. Ruxolitinib provides a patient new hope
that suffers from fatal complications associated with stem cell transplants.
📚𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝
𝐒𝐚𝐦𝐩𝐥𝐞
𝐏𝐃𝐅
𝐂𝐨𝐩𝐲@
https://www.businessmarketinsights.com/sample/BMIRE00028486
Researchers are further investigating the use of stem cell therapy
in treating autoimmune disorders. For example, stem cells can turn into the
cells of damaged organs and are used in treating autoimmune diseases. Treatment
is carried out using mesenchymal stem cells or fetal stem cells. Hematopoietic
stem cells are currently used for treating more than 80 medicals conditions,
including immune system diseases, blood disorders, neurological disorders,
metabolic disorders, genetic disorders, and cancer types such as leukemia and
lymphoma.
𝐓𝐡𝐞 𝐋𝐢𝐬𝐭
𝐨𝐟
𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬
MEDIPOST
RichSource
BioTime, Inc.
Mesoblast Limited
U.S. Stem Cell, Inc.
TiGenix NV
AlloSource
NuVasive Inc
📚𝐅𝐮𝐥𝐥
𝐑𝐞𝐩𝐨𝐫𝐭
𝐋𝐢𝐧𝐤
@ https://www.businessmarketinsights.com/reports/north-america-stem-cell-therapy-market
·
Segments Covered
By Type
- Adult
Stem Cell Therapy
- Embryonic
Stem Cell Therapy
- Induced
Pluripotent Stem Cell Therapy
- Other
Stem Cell Therapy
By Treatment
- Allogeneic
- Autologous
By Application
- Musculoskeletal
- Dermatology
- Cardiology
- Drug
Discovery & Development
- Other
Applications
By End User
- Hospitals
& Specialty Clinics
- Academic
& Research Institutes
The Future Outlook:
The North American stem cell therapy
market is poised for significant growth in the coming years. The increasing
prevalence of chronic diseases, the aging population, and the growing demand
for innovative treatment options are driving market expansion. Advances in stem
cell research, coupled with regulatory clarity and improved reimbursement
policies, will further accelerate market growth.
The market is expected to witness a
shift towards personalized stem cell therapies, with iPSCs playing a prominent
role. The development of off-the-shelf stem cell products, derived from
allogeneic sources, will also contribute to market growth.
The future of stem cell therapy in
North America is bright, with the potential to revolutionize the treatment of a
wide range of diseases and improve the lives of millions of patients. However,
navigating the complex regulatory landscape, addressing ethical concerns, and
overcoming reimbursement challenges will be crucial for realizing the full
potential of this transformative field. The continued investment in research
and development, coupled with strong collaborations and a focus on patient
safety, will pave the way for a future where stem cell therapies are a
mainstream treatment option.
Comments
Post a Comment